NO905301L - Malaria - vaksine. - Google Patents

Malaria - vaksine.

Info

Publication number
NO905301L
NO905301L NO90905301A NO905301A NO905301L NO 905301 L NO905301 L NO 905301L NO 90905301 A NO90905301 A NO 90905301A NO 905301 A NO905301 A NO 905301A NO 905301 L NO905301 L NO 905301L
Authority
NO
Norway
Prior art keywords
malaria
infection
repeating
parasites
immunogenic determinants
Prior art date
Application number
NO90905301A
Other languages
English (en)
Other versions
NO905301D0 (no
Inventor
Mitchell Stuart Gross
Daniel Matthew Gordon
Michael Richard Hollingdale
Original Assignee
Smithkline Beecham Corp
Us Army
Biomedical Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp, Us Army, Biomedical Res Inst filed Critical Smithkline Beecham Corp
Publication of NO905301D0 publication Critical patent/NO905301D0/no
Publication of NO905301L publication Critical patent/NO905301L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Vaksiner mot infeksjon ved parasitter av slekten Plasmodium, polypeptider egnet som terapeutiske midler for inhibering av infeksjon ved malaria-parasitter, hvilke polypeptider omfatter immunogene determinanter fra regioner i et Plasmodiura-overflate-protein som flankerer et sentralt repeterende område i dette og færre enn alle repeterende immunogene determinanter fra det repeterende området; og fremgangsmåter for behandling av mennesker mot malariainfeksjon.
NO90905301A 1989-12-08 1990-12-07 Malaria - vaksine. NO905301L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44774689A 1989-12-08 1989-12-08

Publications (2)

Publication Number Publication Date
NO905301D0 NO905301D0 (no) 1990-12-07
NO905301L true NO905301L (no) 1991-06-10

Family

ID=23777585

Family Applications (1)

Application Number Title Priority Date Filing Date
NO90905301A NO905301L (no) 1989-12-08 1990-12-07 Malaria - vaksine.

Country Status (18)

Country Link
EP (1) EP0432965A1 (no)
JP (1) JPH0673097A (no)
KR (1) KR910011897A (no)
CN (1) CN1053814A (no)
AU (1) AU634837B2 (no)
CA (1) CA2031468A1 (no)
FI (1) FI906051A (no)
HU (1) HUT56882A (no)
IE (1) IE904412A1 (no)
IL (1) IL96579A0 (no)
MA (1) MA22097A1 (no)
MY (1) MY105313A (no)
NO (1) NO905301L (no)
NZ (1) NZ236357A (no)
PL (1) PL288140A1 (no)
PT (1) PT96132A (no)
ZA (1) ZA909838B (no)
ZW (1) ZW19090A1 (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ233255A (en) * 1989-04-11 1993-02-25 Chiron Corp Plasmodium cs protein analogues lacking one or more of the repeat epitopes, and containing at least one nonrepeat flanking epitope
US5972351A (en) * 1992-04-03 1999-10-26 Isis Innovation Limited Plasmodium falciparum MHC class I-restricted CTL epitopes derived from pre-erythrocytic stage antigens
KR950702635A (ko) * 1992-07-31 1995-07-29 크리스틴 헬렌 수덴 감쇠 박테리아에서 재조합 융합 단백질의 발현(Expression of recombinant fusion proteins in attenuated bacteria)
GB9401787D0 (en) 1994-01-31 1994-03-23 Medeva Holdings Bv Vaccine compositions
CA2168459C (en) * 1993-07-30 2002-10-01 Mohammed Anjam Khan Fusion proteins containing the c-terminal of tetanus toxin linked to a heterologous protein
AU7724894A (en) * 1993-09-10 1995-03-27 New York University Compositions and methods for inhibiting hepatocyte invasion by malarial sporozoites
GB9401795D0 (en) * 1994-01-31 1994-03-23 Medeva Holdings Bv Vaccines
GB2295394B (en) * 1994-01-31 1997-09-24 Medeva Holdings Bv DNA encoding a fusion protein comprising the C fragment of tetanus toxin
ES2371066T3 (es) * 2002-11-20 2011-12-27 Sanaria Inc. Vacuna para la prevención del paludismo.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN86100979A (zh) * 1985-02-07 1986-12-17 史密丝克莱恩贝克曼公司 疟疾疫苗的制备方法
IT1196501B (it) * 1986-07-16 1988-11-16 Eniricerche Spa Polipeptide utile per la preparazione di vaccini per la malaria e di kits diagnostici per la determinazione di affezioni malariche
WO1988005817A1 (en) * 1987-01-30 1988-08-11 Smith Kline - Rit S.A. Expression of the p. falciparum circumsporozoite protein by yeast
CA2015722A1 (en) * 1989-05-03 1990-11-03 Mitchell S. Gross Malaria vaccine

Also Published As

Publication number Publication date
NZ236357A (en) 1993-01-27
ZA909838B (en) 1992-05-27
PT96132A (pt) 1991-09-30
IE904412A1 (en) 1991-06-19
NO905301D0 (no) 1990-12-07
AU634837B2 (en) 1993-03-04
MA22097A1 (fr) 1991-12-31
ZW19090A1 (en) 1991-04-10
FI906051A0 (fi) 1990-12-07
IL96579A0 (en) 1991-09-16
CA2031468A1 (en) 1991-06-09
KR910011897A (ko) 1991-08-07
MY105313A (en) 1994-09-30
HU908128D0 (en) 1991-06-28
JPH0673097A (ja) 1994-03-15
FI906051A (fi) 1991-06-09
EP0432965A1 (en) 1991-06-19
CN1053814A (zh) 1991-08-14
HUT56882A (en) 1991-10-28
AU6777490A (en) 1991-06-13
PL288140A1 (en) 1991-10-21

Similar Documents

Publication Publication Date Title
NO922275L (no) Aryletere, deres fremstilling og fremgangsmaate for behandling
NO893769D0 (no) Fremgangsmaate for behandling av naturgass.
IT1229845B (it) Procedimento per la preparazione di perfluoropolieteri perossidici.
MX9204625A (es) Composicion farmaceutica para el tratamiento de una especie de mamifero, que sufre de deficiencia cardiaca congestiva.
FI953608A (fi) Rokoteyhdisteet ja menetelmä immuunireaktion aikaansaamiseksi limakalvossa järjestelmällisellä rokottamisella
HK1087018A1 (en) Peptide-based passive immunization therapy for treatment of atherosclerosis
NO905301L (no) Malaria - vaksine.
IL102092A0 (en) Vaccine and treatment method for human immunodeficiency virus
ITBO910182A1 (it) Apparecchiatura per trattamenti di emodiafiltrazione.
FR2669346B1 (fr) Vaccin a poxvirus recombinant contre le virus de la rougeole.
ES2045348T3 (es) Metodo para preparar derivados de lactamimida para el tratamiento o la prevencion de paludismo farmaco-resistente.
EP0252588A3 (en) Process for the isolation and purification of p. falciparum cs protein expressed in recombinant e. coli, and its use as a vaccine
DK0975360T3 (da) Bovint respiratorisk og enterisk coronavirus som vaccine
NO934055D0 (no) Fremgangsmaate for utvinning av dimetylamin- eller trimetylamindehydrogenaser, dehydrogenaser utvunnet ved denne og anvendelse av dem
DK0802796T3 (da) Kyllingeanæmimiddel-slagtekyllingevaccine
NO890565L (no) Forhindring og behandling av retroviral sykdom.
WO2004030607A3 (en) Peptide-based passive immunization therapy for treatment of atherosclerosis
NO893948D0 (no) Bornitrogenpolymerer, fremgangsmaate for deres fremstilling og anvendelse som forloepere.
DK0792347T3 (da) Fremgangsmåder til fremstilling af forbedrede antigene Heliobacter sp. og vacciner omfattende samme
ITAL910005A0 (it) Processo per la realizzazione di strutture protesiche dentali.
IT1233419B (it) Peptidi sintetici immunologicamente attivi utili per la preparazione di un vaccino antimalaria
NO980275L (no) Dobbelt virusinaktivert humant blodplasma, blodplasmaderivater fremstilt derav og fremgangsmåte for deres fremstilling
DK1204421T3 (da) Stressprotein-peptidkomplekser som vacciner mod intracellulære patogener
FR2648712B1 (fr) Vaccin contre le virus de la leucemie bovine
ITMI911535A1 (it) Derivati di una pirrolo-piridina, un procedimento per la loro preparazione e composizioni terapeutiche che li contengono.